<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">46318680X</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180406164856.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170326e20070801xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/s00726-007-0534-z</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/s00726-007-0534-z</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Polyamine analogues - an update</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[H. M. Wallace, K. Niiranen]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Summary.: The polyamines are growth factors in both normal and cancer cells. As the intracellular polyamine content correlates positively with the growth potential of that cell, the idea that depletion of polyamine content will result in inhibition of cell growth and, particularly tumour cell growth, has been developed over the last 15 years. The polyamine pathway is therefore a target for development of rationally designed, antiproliferative agents. Following the lessons from the single enzyme inhibitors (α-difluoromethylornithine DFMO), three generations of polyamine analogues have been synthesised and tested in vitro and in vivo. The analogues are multi-site inhibitors affecting multiple reactions in the pathway and thus prevent the up-regulation of compensatory reactions that have been the downfall of DFMO in anticancer chemotherapy. Although the initial concept was that the analogues may provide novel anticancer drugs, it now seems likely that the analogues will have wider applications in diseases involving hyperplasia.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Springer-Verlag, 2007</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Keywords: Cancer - Spermidine - Spermine - Polyamine analogues - DFMO - Disease</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">AOE-PU : N-[2-aminooxyethyl]-1,4-diaminobutane</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">APA : 1-aminooxy-3-aminopropane</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">AP-APA : 1-aminooxy-3-N-[3-aminopropyl]-aminopropane</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">BCNU : 1,3-bis(2-chloroethyl)-1-nitrosourea</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">BEHSpm/DEHSpm/BE-4-4-4 : N 1,N 14-bis(ethyl)-homospermine</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">BENSpm/DENSpm/BE-3-3-3 : N 1,N 11-bis(ethyl)-norspermine</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">BES : N 1,N 8-bis(ethyl)spermidine</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">BESpm/DESpm/BE-3-4-3 : N 1,N 12-bis(ethyl)spermine</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">CHENSpm : N 1-ethyl-N 11-((cycloheptyl)methyl)-4,8-diazaundecane</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">CPENSpm : N 1-ethyl-N 11-((cyclopropyl)methyl)-4,8-diazaundecane</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">DFMO : α-difluoromethylornithine</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">IPENSpm : N 1-ethyl-N 11-((isopropyl)methyl)-4,8-diazaundecane</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">MGBG : methylglyoxal bis(guanylhydrazone)</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">ODC : ornithine decarboxylase</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">SAMDC : S-adenosylmethionine decarboxylase</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">SSAT : spermidine/spermine N 1-acetyltransferase</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Wallace</subfield>
   <subfield code="D">H. M.</subfield>
   <subfield code="u">Department of Medicine and Therapeutics, School of Medicine and School of Medical Sciences, University of Aberdeen, Aberdeen, UK</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Niiranen</subfield>
   <subfield code="D">K.</subfield>
   <subfield code="u">Department of Medicine and Therapeutics, School of Medicine and School of Medical Sciences, University of Aberdeen, Aberdeen, UK</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Amino Acids</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">33/2(2007-08-01), 261-265</subfield>
   <subfield code="x">0939-4451</subfield>
   <subfield code="q">33:2&lt;261</subfield>
   <subfield code="1">2007</subfield>
   <subfield code="2">33</subfield>
   <subfield code="o">726</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/s00726-007-0534-z</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">review-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/s00726-007-0534-z</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Wallace</subfield>
   <subfield code="D">H. M.</subfield>
   <subfield code="u">Department of Medicine and Therapeutics, School of Medicine and School of Medical Sciences, University of Aberdeen, Aberdeen, UK</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Niiranen</subfield>
   <subfield code="D">K.</subfield>
   <subfield code="u">Department of Medicine and Therapeutics, School of Medicine and School of Medical Sciences, University of Aberdeen, Aberdeen, UK</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Amino Acids</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">33/2(2007-08-01), 261-265</subfield>
   <subfield code="x">0939-4451</subfield>
   <subfield code="q">33:2&lt;261</subfield>
   <subfield code="1">2007</subfield>
   <subfield code="2">33</subfield>
   <subfield code="o">726</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
